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Introduction
Cancer chemoprevention with edible plants and/or their bioactive constituents is appealing because of their safety, epidemiological evidence of risk reduction, preclinical indication of preventive efficacy, and cost-effectiveness. Cruciferous vegetables are a rich source of cancer chemopreventive phytochemicals collectively known as isothiocyanates (ITCs) (1, 2) . Cancer chemoprevention by ITCs, which occur naturally as thioglucoside conjugates in widely consumed vegetables such as watercress, garden cress, mustard, and broccoli, was first documented by Wattenberg more than three decades ago (3) . Phenethyl isothiocyanate (PEITC) abundant in watercress and the garden cress constituent benzyl isothiocyanate (BITC) were shown to inhibit breast cancer induced by 7,12-dimethylbenz[a]anthracene in rats when administered 4 hour before the carcinogen treatment (3) . Since then, the chemopreventive activity of ITCs was extended against other chemical carcinogens (1, 2) . Epidemiological association of cancer risk reduction with increasing intake of cruciferous vegetables provides additional support for their chemopreventive effect (4) (5) (6) . PEITC and BITC have been studied extensively for their anticancer preventive efficacy in preclinical models as well as mechanistic characterization (1, 2) . The ClinicalTrials.gov lists 3 completed or ongoing clinical trials on PEITC or watercress juice. On the other hand, preclinical efficacy and mechanistic studies on SFN have primarily focused on the synthetic racemic (D,L-SFN) analogue of naturally-occurring L-isomer (2) . Majority of the ongoing or completed clinical trials on SFN in healthy volunteers or cancer patients have used standardized broccoli sprout extract.
Our interest in ITCs was initially sparked by epidemiological studies suggesting an inverse relationship between intake of cruciferous vegetables and the risk of prostate cancer (7, 8) . Prostate adenocarcinoma remains a leading cause of cancer mortality among American men despite a comprehensive understanding of the underlying biology, genomic landscape, and the risk factors (9) (10) (11) (12) . Population-based evidence prompted us to test the efficacy of PEITC and SFN for prevention of prostate cancer using a transgenic mouse model (Transgenic Adenocarcinoma of Mouse Prostate; TRAMP) (13) (14) (15) . Dietary administration of PEITC (3 μmol/g diet) for 19 weeks to male TRAMP mice resulted in a statistically significant decrease in the incidence of poorly-differentiated prostate cancer when compared to mice fed with basal diet (13) . Oral SFN administration (6 μmol/mouse three times per week) inhibited the incidence of prostatic intraepithelial neoplasia and well-differentiated cancer, but not poorly-differentiated cancer in TRAMP mice (14) . However, inhibition of poorly-differentiated prostate cancer by oral SFN was achievable with co-administration of an autophagy inhibitor (chloroquine) as SFN is known to induce cytoprotective autophagy (15, 16) . SFN was also effective in preventing pulmonary metastasis in the TRAMP mouse model (14) . Feeding of 240 mg of broccoli sprout/day to TRAMP mice exhibited retardation of prostate tumor growth (17) . The growth of PC-3 and LNCaP human prostate cancer cells subcutaneously implanted in athymic mice was retarded significantly by PEITC or SFN administration (18) (19) (20) . PEITC also exhibited in vivo growth inhibitory activity against a cell line (TRAMP-C1) derived from a TRAMP tumor (21) . PEITC and SFN have been the focus of intense mechanistic studies to gain insights into the biology of prostate cancer chemoprevention by these agents (2, 18, 19, (21) (22) (23) (24) .
Mechanisms of prostate adenocarcinoma chemoprevention by PEITC and SFN include apoptotic or autophagic cell death induction (autophagy is cytoprotective for SFN),
Materials and Methods

Ethics statement
The use of mice for the in vivo studies was approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Prostate tumor tissues from our previously published studies (15, 26) were used to determine the in vivo effect of PEITC and SFN administration on CXCR4 protein expression. For the in vivo xenograft experiment with PEITC, PC-3 cells stably expressing luciferase were injected subcutaneously on flank of each mouse. Control mice were treated with phosphate-buffered saline (PBS; control) or 9 μmol PEITC (oral intubation) in 0.1 mL PBS five times per week for 38 days (26) . PEITC treatment was started on the day of tumor cell injection (26) . For the SFN-TRAMP study, 4 week old male TRAMP mice were treated with PBS (control) or 1 mg SFN in PBS three times/week for 15-18 weeks (15).
Reagents and cell lines
Majority of the cell culture reagents were purchased from Invitrogen-Life Technologies, whereas RPMI 1640 medium was from Mediatech. Sources of the antibodies were as follows: anti-CXCR4 antibody was from Abcam, an antibody specific for detection of S473 phosphorylated AKT was from Cell Signaling Technology; anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody was from GeneTex; antibodies against phospho-and total extracellular-signal regulated kinases (ERK) were purchased from Santa 7 Collection and last authenticated in 2012. Each cell line was found to be of human origin and free of pathogen contamination. PC-3 cells stably transfected with CXCR4 plasmid (hereafter abbreviated as CXCR4_PC-3) or empty vector (Neo_PC-3) have been described previously (27) .
Western blotting
After treatment, cells were collected and lysed as described by us previously (28).
TRAMP tumor tissues were processed as previously described (13) . Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and wet transferred onto a membrane. Western blotting was performed as described previously (28) except that dilution of CXCR4 antibody and membrane exposure time were optimized. Enhanced chemiluminescence reagent was used for immunodetection of the band.
Immunofluorescence microscopy
LNCaP or PC-3 cells were plated on coverslips in 12-well plates, allowed to attach overnight, and then exposed to PEITC, BITC, SFN or DMSO (control) for 24 hours. After washing with BD Perm/Wash™ buffer, cells were fixed with fixation/permeabilization solution supplied in the kit at 4°C for 10 minutes. Cells were washed again, blocked with 0.5% bovine serum albumin and 0.15% glycine in PBS for 1 hour, and incubated with anti-CXCR4 antibody overnight at 4°C or at room temperature for 1 hour. After washing with BD Perm/Wash™ buffer, Alexa Fluor 488-conjugated secondary antibody was added (1 hour at room temperature). Subsequently, cells were washed and treated with DAPI (10 ng/mL) for 5 minutes at room temperature to stain nuclear DNA. Cells were washed with PBS and examined under a fluorescence microscope at 100× objective magnification. 8 with the desired ITCs were isolated using RNeasy kit. The cDNA was synthesized with the use of SuperScript III reverse transcriptase and oligo(dT) 20 primer. PCR was performed using specific primers: CXCR4 forward: 5'-GAAGCTGTTGGCTGAAAAGG -3' and CXCR4 reverse: 5'-GAGTCGATGCTGATCCCAAT-3' (PCR product size, 345 bp); with the following amplification conditions: 94ºC for 5 minutes, 28 cycles at 94ºC for 15 seconds, 54ºC for 30 seconds, 72ºC for 1 min and extension at 72 ºC 10 minutes. Quantitative PCR (qPCR) was done using 2x SYBR Green master mix (Applied Biosystems-Life Technologies) under same conditions, with the number of cycles changed to 40. Relative gene expression was calculated using the method described by Livak and Schmittgen (29) .
Measurement of CXCL12 secretion
Analysis of CXCL12 secretion was performed using a commercially available kit.
PC-3 cells were plated into six-well plates, allowed to attach, and then exposed to PEITC, BITC, SFN or DMSO (control) for 24 hours. Conditioned medium was collected and spun down to remove debris and stored at -80°C. CXCL12 was measured in the medium by an immunoassay kit from R&D Systems. The concentration in the medium was calculated using a standard curve from serially diluted CXCL12 provided with the kit.
RNA interference
PC-3 cells were seeded in six-well plates and transfected at 70% confluency with a nonspecific (control) small interfering RNA (siRNA) or CXCR4-targeted siRNA (100 or 200 nmol) using Oligofectamine. Twenty-four hours post transfection cells were treated with DMSO or the test agent for an additional 24 hours. Cells were collected and processed for either immunoblotting, cell migration or wound healing assay. Knockdown of CXCR4 was confirmed by western blotting. 
Cell viability assay
Cell viability was determined by trypan blue dye exclusion assay as described by us previously (30) .
Statistical analysis
One way-analysis of variance (ANOVA) with Dunnett's adjustment was used to determine statistical significance of difference for dose-response studies whereas Bonferroni's test was used for multiple comparisons (e.g., between Neo_PC-3 and 
Results
ITCs downregulated CXCR4 expression in prostate cancer cells
We used androgen-sensitive (LNCaP and 22Rv1) and androgen-independent human prostate cancer cells (C4-2 and PC-3) and pharmacologically relevant concentrations of PEITC, BITC, and SFN ( 
ITCs had no effect on CXCL12 expression or secretion
We next determined the effect of ITCs on expression and secretion of CXCR4 ligand CXCL12. Expression of CXCL12 was not affected by PEITC, BITC or SFN at least in PC-3 cells as determined by immunofluorescence microscopy (data not shown). As shown in 
Effects on PEITC and SFN administration on tumor CXCR4 protein level in vivo
In a PC-3 xenograft study with 5 times/week oral administration of 9 μmol PEITC, the average tumor volume (mean ± SD) in control mice (879.2 ± 284.5) was about 1.9-fold higher compared with PEITC-treated mice (P=0.068) (26) . Fresh frozen tumor tissues from this study (26) were used to determine the effect of PEITC administration on CXCR4 protein level in vivo. As shown in Fig. 3A , CXCR4 protein was detectable in most of the control PC-3 xenografts. The level of CXCR4 protein was lower by about 74% in the PC-3 xenografts from PEITC-treated mice when compared with controls with a P= 0.03 by unpaired Student's t-test (n = 7 for control and n = 8 for PEITC treatment group) (Fig. 3B) .
We have shown previously that the incidence of well-differentiated cancer in the dorsolateral prostate of TRAMP mice is decreased by about 25% upon oral intubation with 1 mg SFN three times/week (15) . Western blotting for CXCR4 protein also showed its suppression in the tumors from SFN-treated TRAMP mice relative to control (Fig. 3C) but the difference was insignificant possibly due to small sample size (Fig. 3D) . Nevertheless, these results provided in vivo evidence for suppression of CXCR4 expression in prostate tumors upon treatment with PEITC and SFN.
Overexpression of CXCR4 conferred significant protection against ITCs-mediated inhibition of wound healing
A scratch wound healing assay was performed to determine the functional significance of CXCR4 downregulation by ITCs. Expression of CXCR4 protein was 2.6-fold higher in CXCR4_PC-3 cells in comparison with empty vector transfected Neo_PC-3 cells (Fig. 4A) 
effect was nearly fully abolished by CXCR4 overexpression (Fig. 4B,C) . Similar experiments were performed using SFN, but the results were inconclusive (data not shown). We also determined the effect of CXCR4 knockdown in PC-3 cells using a siRNA (Fig. 4A ) on wound healing inhibition by PEITC and BITC (Fig. 4D) . The wound healing inhibition by PEITC, but not BITC was significantly augmented by CXCR4 knockdown. Difference between PEITC and BITC is not surprising as these compounds are known to exhibit mechanistic differences despite close structural similarity (1,2).
RNA interference of CXCR4 augmented PEITC-and BITC-mediated inhibition of PC-3 cell migration
Fig 5A depicts PC-3 cell migration that was decreased by 28% (P < 0.05) by CXCR4 knockdown alone in the absence of PEITC treatment. Exposure to PEITC also resulted in a significant inhibition of migration capacity of PC-3 cells (Fig. 5B) .
PEITC-mediated inhibition of PC-3 cell migration was modestly but statistically significantly augmented by RNA interference of CXCR4 but this effect was relatively more pronounced for BITC (Fig. 5B) .
Inhibition of cell migration and cell viability by ITCs in PC-3 cells was attenuated by ectopic expression of CXCR4
Cell migration was more intense for CXCR4 overexpressing cells compared with Neo_PC-3 cells (Fig. 5C) . PEITC treatment decreased cell migration in Neo_PC-3 cells but this effect was abolished in CXCR4 overexpressing cells (Fig. 5D ). CXCR4 overexpression also conferred partial but significant protection against BITC-mediated inhibition of PC-3 cell migration (Fig. 5D ).
Western blotting for CXCR4 was performed using lysates from Neo_PC-3 and CXCR4_PC-3 cells after 24 hour treatment with DMSO (control) or 2.5 and 5 μmol/L PEITC.
Generally consistent with the results in un-transfected PC-3 cells (Fig. 2A) 
CXCR4 protein was decreased by 50-70% after PEITC treatment in Neo_PC-3 cells (Fig.   6A ). PEITC treatment was relatively less effective in downregulating CXCR4 protein in CXCR4_PC-3 cells in comparison with Neo_PC-3 cells (Fig. 6A) . Viability of Neo_PC-3 cells was significantly decreased after 24 hour treatment with PEITC, BITC, and SFN; albeit in the order of PEITC > BITC > SFN (Fig. 6B ). Similar to cell migration assay, CXCR4 overexpression conferred significant protection against cell viability inhibition by each compound (Fig. 6B) . Previous studies have shown that CXCR4/CXCL12 signaling activates AKT, which is a pro-survival signal (31) . In agreement with these results, S473 phosphorylation of AKT was >2-fold higher in CXCR4_PC-3 cells when compared with empty vector transfected control cells (Fig. 6C) . Phosphorylation of AKT was decreased to varying extent upon treatment of CXCR4_PC-3 and Neo_PC-3 cells with each compound. A modest attenuation of pAKT suppression upon CXCR4 overexpression in the presence of 2.5 µmol/L PEITC or BITC was not consistent in different experiments. Previous studies have also shown ERK activation in CXCR4 signaling (25) . Level of phospho-ERK2 was modestly higher in CXCR4_PC-3 cells than in Neo_PC-3 (Fig. 6D ), but ERK activation was not affected by ITCs in either cell type (Fig. 6D) . These results indicated that CXCR4-mediated protection against cell proliferation inhibition by ITCs was independent of AKT or ERK activation.
Discussion
The present study reveals that CXCR4 is a novel target of widely-studied cancer chemopreventive ITCs at least in prostate cancer cells. Despite a close structural similarity between PEITC and BITC (Fig. 1A) , marked differences have been documented in their cancer protective effect as well as associated mechanisms (2,3). However, CXCR4 seems to be a common target of both these compounds as well as for a commonly studied thioalkyl-type ITC. We also show that CXCR4 downregulation by ITCs is not a cell line-specific effect as both androgen-sensitive and androgen-independent cells are susceptible to CXCR4 down-regulation by ITCs. It is important to point out that downregulation of CXCR4 protein upon 48 h treatment of PC-3 and DU145 cells with 10 µmol/L SFN was documented previously but functional significance of its suppression was not studied (32) .
Since submission of this manuscript, BITC-mediated downregulation of CXCR4 was shown in a human glioma cell line but the functional significance of this observation was not studied (33) .
Even though expression of CXCR4 mRNA is decreased after treatment with ITCs (Fig. 2C) , the upstream mediator(s) of transcriptional repressors remain unknown. It is plausible that CXCR4 downregulation by ITCs is mediated by nuclear factor-κB as this transcription factor, which is a known regulator of CXCR4 expression, is inhibited by ITC treatment in prostate cancer cells (22, 32) . Recent studies have also implicated ERG (ETS-related gene) in transcriptional regulation of CXCR4 (34, 35) , and the possibility of Several studies have evaluated CXCR4 overexpression in prostate and other tumors (25, 43, 44) . Analysis of CXCR4 expression in humans using high-density tissue microarrays from a cohort of over 600 patients revealed significantly elevated levels of this chemokine receptor in localized cancer and metastatic disease (43) . High expression of CXCR4 in metastatic prostate cancers from patients on androgen deprivation therapy was associated with poor survival, but not predictive of clinical response to hormonal therapy (44) . In a mouse model, a positive correlation was observed for CXCL12 levels in tissues with metastatic lesions (45) . Several studies have suggested a role for CXCR4 in metastasis of prostate cancer (46, 47) . Because treatment with PEITC and SFN results in inhibition of distant site metastasis (13, 14, 15) it is reasonable to consider that anti-metastatic activity of ITCs is mediated, at least in part, via downregulation of CXCR4. CXCR4/CXCL12 signaling is mechanistically linked to AKT-1, EGFR, ERK, and MMP-9 in prostate cancer cells (31, 48) . CXCR4 is localized in lipid rafts of prostate cancer cells and initiates AKT phosphorylation (31) . Loss of PTEN results in induction of both CXCR4 and CXCL12 expression and these effects are reversed by AKT inhibition (31) .
Expression of CXCR4 is also increased by overexpression of AKT-1 in DU145 cells (48) .
The present study reveals that CXCR4-mediated attenuation of cell proliferation inhibition by ITCs is independent of AKT or ERK activation status. Other possibilities need to be explored to explain these observations. For example, forced expression of zinc-finger transcription 
factor SLUG in prostate cancer cells causes induction of CXCR4 and CXCL12 leading to promotion of cell migration (49) . The effect of PEITC or SFN on SLUG is not yet known in prostate or other cancers, but we previously reported downregulation of this transcription factor in BITC-treated breast cancer cells (50) . Thus, it is reasonable to conclude that suppression of SLUG likely contributes to cell migration and proliferation inhibition by ITCs.
In conclusion, the present study shows that CXCR4, but not CXCL12, is transcriptionally downregulated after treatment with PEITC, SFN and/or BITC in prostate tumor cells. We show further that CXCR4 downregulation is functionally important as inhibition of cell viability and migration by ITCs is attenuated by its overexpression.
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